OCULOCULAR THERAPEUTIX, INC同业对比
OCULAR THERAPEUTIX, INC 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCUL本股 | $1.5B#7 | — | 2.9x#9 | 29.1x#9 | -18.5%#10 | -37.4%#11 | -519.8%#10 | -51.1%#11 | — | — | -39.6%#10 | — |
| SUPN | $1.7B#2 | — | 1.6x#4 | 2.4x#3 | 8.6%#7 | -152.2%#12 | -8.7%#6 | -3.6%#6 | -4.8%#5 | — | -46.5%#11 | — |
| NUVB | $1.7B#3 | — | 6.6x#11 | 26.5x#8 | 699.0%#1 | 64.0%#5 | -338.7%#9 | -80.6%#12 | -87.4%#8 | — | -7.8%#8 | — |
| RARE | $1.7B#4 | — | — | 2.5x#4 | 20.2%#5 | -1.1%#8 | -79.5%#8 | — | — | — | -49.7%#12 | — |
| TRAX | $1.9B#1 | — | 12.8x#12 | — | — | -1.5%#9 | — | -110.0%#13 | — | — | — | — |
| KLRA | $1.6B#5 | — | 1.5x#3 | — | — | — | — | 0.0%#4 | — | — | — | — |
| ANIP | — | 15.6x#5 | — | — | 43.8%#4 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#1 | — | -23.7%#9 | — |
| INVA | $1.5B#6 | 4.9x#3 | 1.2x#2 | 3.7x#5 | 14.7%#6 | 1059.2%#1 | 39.8%#2 | 22.0%#1 | 14.7%#2 | 5#1 | 16.2%#7 | — |
| ETON | $1.5B#8 | — | 31.4x#13 | 18.3x#7 | 104.9%#3 | -20.4%#10 | -1.1%#5 | -9.9%#8 | -1.8%#4 | 4#2 | 185.2%#2 | — |
| PCRX | $1.5B#9 | 104.0x#6 | 2.2x#5 | 2.0x#1 | 3.6%#8 | 107.0%#3 | 2.6%#4 | 1.0%#3 | 1.0%#3 | — | 64.2%#4 | — |
| ANAB | $1.4B#10 | 8.6x#4 | 135.5x#14 | 6.1x#6 | 157.0%#2 | 90.9%#4 | 96.7%#1 | -125.0%#14 | — | — | 33.1%#5 | — |
| MLYS | $1.4B#11 | — | 2.6x#7 | — | — | 13.0%#7 | — | -28.1%#9 | -41.3%#7 | — | -59.0%#13 | — |
| DMRA | $1.4B#12 | 2.9x#2 | 2.7x#8 | — | — | -878.8%#14 | — | -40.7%#10 | — | — | 230.7%#1 | — |
| KARD | $1.3B#13 | — | 2.2x#6 | — | — | — | — | 0.0%#4 | — | — | — | — |
| LBRX | $1.3B#14 | 1.8x#1 | 4.0x#10 | — | — | 60.1%#6 | — | -7.6%#7 | — | — | 154.2%#3 | — |
| OPK | $1.3B#15 | — | 1.1x#1 | 2.2x#2 | -14.9%#9 | -324.0%#13 | -19.3%#7 | -19058.1%#15 | -13.3%#6 | 4#2 | 26.5%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议